The effect of non-insulin-dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle
- PMID: 8675680
- PMCID: PMC507362
- DOI: 10.1172/JCI118724
The effect of non-insulin-dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle
Abstract
Defects of glucose transport and phosphorylation may underlie insulin resistance in obesity and non-insulin-dependent diabetes mellitus (NIDDM). To test this hypothesis, dynamic imaging of 18F-2-deoxy-glucose uptake into midthigh muscle was performed using positron emission tomography during basal and insulin-stimulated conditions (40 mU/m2 per min), in eight lean nondiabetic, eight obese nondiabetic, and eight obese subjects with NIDDM. In additional studies, vastus lateralis muscle was obtained by percutaneous biopsy during basal and insulin-stimulated conditions for assay of hexokinase and citrate synthase, and for immunohistochemical labeling of Glut 4. Quantitative confocal laser scanning microscopy was used to ascertain Glut 4 at the sarcolemma as an index of insulin-regulated translocation. In lean individuals, insulin stimulated a 10-fold increase of 2-deoxy-2[18F]fluoro-D-glucose (FDG) clearance into muscle and significant increases in the rate constants for inward transport and phosphorylation of FDG. In obese individuals, the rate constant for inward transport of glucose was not increased by insulin infusion and did not differ from values in NIDDM. Insulin stimulation of the rate constant for glucose phosphorylation was similar in obese and lean subjects but reduced in NIDDM. Insulin increased by nearly twofold the number and area of sites labeling for Glut 4 at the sarcolemma in lean volunteers, but in obese and NIDDM subjects translocation of Glut 4 was attenuated. Activities of skeletal muscle HK I and II were similar in lean, obese and NIDDM subjects. These in vivo and ex vivo assessments indicate that impaired glucose transport plays a key role in insulin resistance of NIDDM and obesity and that an additional impairment of glucose phosphorylation is evident in the insulin resistance of NIDDM.
Similar articles
-
Abnormal glucose transport and GLUT1 cell-surface content in fibroblasts and skeletal muscle from NIDDM and obese subjects.Diabetologia. 1997 Apr;40(4):421-9. doi: 10.1007/s001250050696. Diabetologia. 1997. PMID: 9112019
-
Insulin-induced hexokinase II expression is reduced in obesity and NIDDM.Diabetes. 1998 Mar;47(3):387-94. doi: 10.2337/diabetes.47.3.387. Diabetes. 1998. PMID: 9519744
-
Regulation of skeletal muscle hexokinase II by insulin in nondiabetic and NIDDM subjects.Diabetes. 1998 Jul;47(7):1107-13. doi: 10.2337/diabetes.47.7.1107. Diabetes. 1998. PMID: 9648835
-
Studies of gene expression and activity of hexokinase, phosphofructokinase and glycogen synthase in human skeletal muscle in states of altered insulin-stimulated glucose metabolism.Dan Med Bull. 1999 Feb;46(1):13-34. Dan Med Bull. 1999. PMID: 10081651 Review.
-
Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.Dan Med J. 2014 Jul;61(7):B4890. Dan Med J. 2014. PMID: 25123125 Review.
Cited by
-
Use of positron emission tomography (PET) in the assessment of skeletal muscle glucose metabolism.Z Ernahrungswiss. 1997 Dec;36(4):359-63. doi: 10.1007/BF01617828. Z Ernahrungswiss. 1997. PMID: 9467235
-
Inhibition of neutral sphingomyelinases in skeletal muscle attenuates fatty-acid induced defects in metabolism and stress.Springerplus. 2014 May 20;3:255. doi: 10.1186/2193-1801-3-255. eCollection 2014. Springerplus. 2014. PMID: 24892004 Free PMC article.
-
Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance.J Clin Invest. 1998 Jun 1;101(11):2377-86. doi: 10.1172/JCI1557. J Clin Invest. 1998. PMID: 9616209 Free PMC article.
-
Depot-specific regulation of glucose uptake and insulin sensitivity in HIV-lipodystrophy.Am J Physiol Endocrinol Metab. 2006 Feb;290(2):E289-98. doi: 10.1152/ajpendo.00273.2005. Epub 2005 Aug 30. Am J Physiol Endocrinol Metab. 2006. PMID: 16131513 Free PMC article. Clinical Trial.
-
The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes.Diabetologia. 2005 Jan;48(1):83-95. doi: 10.1007/s00125-004-1619-9. Epub 2004 Dec 24. Diabetologia. 2005. PMID: 15619071 Clinical Trial.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials